Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Stanford University
ViroMissile, Inc.
Replimune, Inc.
Tizona Therapeutics, Inc
MacroGenics
Fusion Pharmaceuticals Inc.
University of Southern California
OncoNano Medicine, Inc.
The First Affiliated Hospital of Xinxiang Medical College
Abramson Cancer Center at Penn Medicine
AstraZeneca
Actym Therapeutics, Inc.
Baylor College of Medicine
University of Virginia
Shandong Boan Biotechnology Co., Ltd
Mayo Clinic
Columbia University
Tvardi Therapeutics, Incorporated
Turnstone Biologics, Corp.
National Cancer Institute (NCI)
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
Eli Lilly and Company
NantBioScience, Inc.
Gene Surgery LLC
Pfizer
Arcus Biosciences, Inc.
DNAtrix, Inc.
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Eisai Inc.
National Cancer Institute (NCI)
Atreca, Inc.
Oncorus, Inc.
Fate Therapeutics
Pfizer
Prelude Therapeutics
Herlev Hospital
Quadriga Biosciences, Inc.
Genzada Pharmaceuticals USA, Inc.
Xencor, Inc.
Provectus Pharmaceuticals
Ludwig Institute for Cancer Research
Imperial College London
Incyte Corporation
MacroGenics